{"name":"Raziel Therapeutics Ltd.","slug":"raziel-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNRzdOSk9QYjdPQlBFbFItbmpMU09FcktoeGlvdW5oay1taG1PNnhpRnpwamxlRV9hU0NsRXEtR1dNZ05mY0VTRHUwR0U3cVc5RGZUQ2VPNmlNN2JzaUVWMVNjeU51Y2htTE9KaHJrSUdmM19acjZvcE5pTXVDazRNRHhOWW03SHYyZTMtMW5jSlVYa3drVUhWMnZteGRWWVRYYUFIeTN4NXczYWV4TkIyTGpWN3V6NGFhdkp1c3p4YTZGZjJCOEV6eUc3OU16UTJtaHRzOWd6VzZBSmE4bExfSmd0R3g0QWlZTFRrS3kzN1Z3aGwtbi1xT0dKWUNGNXdKTE80?oc=5","date":"2025-09-05","type":"pipeline","source":"PR Newswire UK","summary":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNR3JSNTlSOG9Ed2x5Mms0ak1VbEFYay1Vc09SclpjcU1NUnVDQVdrV1ROcG4xOXVSd0xTalMzNjBSNDZvUldBR3MzaUNRXzJVRVlkWl9wdWNIZndwVnh4SjVHcl9ZMkVBdi11SkV6SWVqc3RYZk9TdVBrc1BjNllSbms1RFNHV0lGeDN3ck0xUkJXM201aUJOWXlDMy1tZjNhajYzVUVRUVJkMHB0WE5GQUU2V0V4UjduNmFESTVR?oc=5","date":"2025-07-15","type":"deal","source":"Contract Pharma","summary":"365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea - Contract Pharma","headline":"365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQbGdvVFdOQkQyQ016WmtQQ2ZTRU81cWE1VnFFNnFMd2t5bU41Nzh6UURXcVk1YkRHWGkxYlFsMzU1U3VKYnBobGgxSUNBRXZ2VmZiaXhqUnRsclhZbTBIVURxSlF0UmZDM3I4R2E2M0pqcUdSRTdDdDlJdi16QjBCZWU2SzJlalVnXzd1M2kyVFVBaDZ0Rmp1ZlBDeEUtY0FSOHUzN1hiSjAtSWdXN1NWQnZDTE9nbXJGb1VSUkdEQmJFV1ZTcTRkb3lVMVFkcWJyM1ljQTBYSWh1M3BwaTBoMFFVYWJuRHNTYlNjNA?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire UK","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire UK","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPV1I4M3VtaFYtNzRQeFNlX0owb1FzUUllVUQ5cG9sTG1rTHI1UTRObDZoU0NyZXhpQTNxSzdQZnEzV0dYbmNqa25Zb2hMWjZqT0RCV3ZkYUM0cTRzal90bnZ5UTBVaW9DcDFjWVFldERvczZtazNlMGZDM2dPV1ZIeC02MEgyRHdkYlkzUHNtaUR1S3lkS0xVMklaNC1qLTZGc293T2x2YzFhY1BpVzVqV0Vud3I1MEJPaDN1YzVXeDRmbmMyZGVpRWtwWkVHZHZPZXJ2ODByOV9wbUkzSkE?oc=5","date":"2025-03-05","type":"trial","source":"BioPharma APAC","summary":"Raziel Therapeutics Launches Phase 3 Study in China for RZL-012, an Injectable Fat Reduction Treatment - BioPharma APAC","headline":"Raziel Therapeutics Launches Phase 3 Study in China for RZL-012, an Injectable Fat Reduction Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNZjVyUVRCNTZDcUxOYlNzd1dRSWZrUE1Qdlh1cEVNY2VHT0c0YU93U1ZuVnpCbzBlMDBkcUxGeHlFbktQbmhaQmpLOGF4bm92cDUxbHpTLUtlbzJ2amVnVy1ieXlsWElUcDRWQ0pYc1Q1N2c1R3hzS1lGcTM4R3dIV1hyTS1Ma0JCRlc5MGduX3V0REYxOVN3QmUwSVFReUVVX3VaUUV3SUJsTGlZTzYtZmFua0NIUnprUmp1V1N0amtUOHNzMTZPbEdQQkhpZ3NnYVI3cENlY25CcXktR3dmaFR0aGIzUExRaE95WmYwRzk1b0kzenNaLWVRMVk5Zw?oc=5","date":"2025-02-27","type":"pipeline","source":"GlobeNewswire","summary":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight - GlobeNewswire","headline":"WEGOVY Marks Significant Growth in Market Share Across the 7MM for Obesity Treatment | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPRFl4SElTVnNjcUxrZFBZN0VvbElnQWpyTlQ0bkVEX0dZMk5CMklGaXVxZmlZY0NSZkxHaVhOTk1vZmdtWkpNS0NScmo0dlppckdxMjVzVzZkVVpyMHo1b3BtZnBvYXdMSFpTMVRTaTBzMGZGYWtSRDJVZ1dYNGY3S05lSkpnUWduRVh6WGR3ZFVyOFlfWGRKUUFBaUFwZFpG?oc=5","date":"2024-12-17","type":"trial","source":"BioWorld News","summary":"Caliway’s CBL-514 meets endpoints in reducing abdominal fat - BioWorld News","headline":"Caliway’s CBL-514 meets endpoints in reducing abdominal fat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOZF9HR0cwWTltNmtaWGNhQ0JxbUxDaF8tdWhIZHRYRUg2NkpzUUFReU5MSGRTcy05QU55cFpYZ1VPLS1YV2hWeUdQOXl5dlRwbDNUek5iOUVGU01KSVMyd3k3dkFjeDdDQXgtTDRidlFuNW5UcHJXNHlRRTZSZm1zX0lsYzBfTmJPaWFuUUowaWJIbWxWZE1idHBWak9leWpBLTFzNUdLX18wcjkyaFlfT2JIbkFZTGViTndzSHJZQ3pWX01xeTRCV1hhRTlOQXNwZVVIM1llS1dsLWJwTXRpLW9sbW5MWUV3SmRxR1VESVJ4amJ3THRnTm9OcHdsV1ZsTHlzYjhOU2dCZGpDUkNQT3o2X0d2My1QakpfVTN0X3c4elN1a2FtdnN0ZXk4dw?oc=5","date":"2024-08-06","type":"trial","source":"GlobeNewswire","summary":"Obesity Clinical Trial Pipeline Appears Robust With 80+ Key - GlobeNewswire","headline":"Obesity Clinical Trial Pipeline Appears Robust With 80+ Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPTm1iOVZkUkcwdDV3cF90OEpGZ3VLbGdJQ0ZaWDNFa3BlMUF0ZS1CUTB5TWV2eHlFbkh1cXl6RjJFaHZlR1RVLVNTd1FDM19RRExiaEJIYndWWEk5ekp5aUlXNXRNbXFIYkFFUDlhOGdSRlRNZDlSN2IwekIyZ0ZES1FfdTVFY0JacTY3Z3Q3WE9kbUtERl9kVlFIY3Yzd2pqN19Wc1VHeHhNNU9ZZF9wa29qeDNDZC1wVFRFOGVSQTlRdTNNem5XRnJWR1lLNkRJOXBIZ2lSd0E0WU44dXhaaVo1dlkwdjR2Q3F6bUZkM3JkamtCTVYyMEhDQVRZLXBqd0VHWGctQmtLb2tyaC1mSk9RcEZVZ2RtUzdQZDRVcW9oLUV1VHMwbnVvczVlUUFTX3dz?oc=5","date":"2024-07-23","type":"trial","source":"GlobeNewswire","summary":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ - GlobeNewswire","headline":"GLP Agonist Clinical Trial Pipeline Appears Robust With 20+","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-06-18","type":"pipeline","source":"prnewswire.com","summary":"Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Bios","headline":"Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBDUGhGc0VIeFVlMnVjNGZCeVd0UjFBUjE5OElqQW42Sk5RQkQ4cl9waERQM2p6NVloWS1wdUNtenN6MElyRGhCSVFNV0t5clhyTUxDazRuZFlyWkJFR2ozRm52MXRlV2hGQlkwbjZORy1Tc3RCV3dv?oc=5","date":"2020-09-22","type":"deal","source":"calcalistech.com","summary":"Double-chin reducing Israeli startup closes $74 million China licensing deal - calcalistech.com","headline":"Double-chin reducing Israeli startup closes $74 million China licensing deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}